Ondine Biomedical Inc (OBI) NPV

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
Ondine Biomedical gets $4m investment from HCA Healthcare subsidiary
27 January 2025 15:44
(Sharecast News) - Ondine Biomedical announced a $4m equity investment from hInsight-NX, a subsidiary of US medical facilities giant HCA Healthcare, on Monday, extending its cash runway through to the fourth...
-
Ondine enrols first patient in phase three clinical trial
30 December 2024 10:02
(Sharecast News) - Ondine Biomedical announced the launch of its phase three clinical trial for 'light-activated antimicrobial therapy to prevent surgical site infections' (LANTERN) on Monday,...
-
Ondine enrols first patient in phase three clinical trial
30 December 2024 10:02
(Sharecast News) - Ondine Biomedical announced the launch of its phase three clinical trial for 'light-activated antimicrobial therapy to prevent surgical site infections' (LANTERN) on Monday,...
-
Ondine Biomedical to start phase three Steriwave clinical trial
17 December 2024 12:32
(Sharecast News) - Ondine Biomedical announced on Tuesday that it would begin its phase three 'LANTERN' clinical trial for its novel nasal photodisinfection technology, branded as Steriwave outside...
-
Ondine raising £8.5m to fund US clinical trial
1 November 2024 10:47
(Sharecast News) - Ondine Biomedical announced a proposed minimum £8.5m fundraising through a placing and subscription of new shares on Friday, priced at 8.5p each, to support the US phase three clinical...
-
Ondine Biomedical gets UAE approval for Steriwave
18 October 2024 12:04
(Sharecast News) - Ondine Biomedical announced on Friday that it has received regulatory approval to market its 'Steriwave' nasal decolonisation technology in the United Arab Emirates.
-
Ondine Biomedical's Steriwave added to NHS Supply Chain
21 June 2024 13:14
(Sharecast News) - Life science company Ondine Biomedical announced on Friday that its 'Steriwave' nasal photodisinfection treatment was now available through the NHS Supply Chain.
-
Ondine reports significant financial growth
24 April 2024 15:09
(Sharecast News) - Ondine Biomedical reported significant growth in a trading update on Wednesday, with revenues doubling to $1.2m in 2023, driven by expanded hospital deployments of 'Steriwave'.
-
Ondine Biomedical assessing Steriwave with Yorkshire partners
5 March 2024 13:50
(Sharecast News) - Ondine Biomedical announced on Tuesday that it is joining forces with the Mid Yorkshire Teaching NHS Trust, Health Innovation Yorkshire and Humber, and the York Health Economics Consortium...
-
Ondine raises $3.6m to help commercialise Steriwave
13 December 2023 14:43
(Sharecast News) - Life sciences company Ondine Biomedical has successfully raised CAD 4.91m ($3.62m), it announced on Wednesday, bolstering its efforts to commercialise its photodisinfection technology...
-
Ondine reports strong research findings from Canadian hospitals
23 October 2023 12:15
(Sharecast News) - Ondine Biomedical announced ground-breaking research findings from Vancouver General and University of British Columbia (UBC) Hospitals in British Columbia, Canada, on Monday, after they...
-
Ondine announces expanded Canadian availability of Steriwave
13 October 2023 16:15
(Sharecast News) - Life sciences company Ondine Biomedical announced the expansion of the availability of its Steriwave nasal photo disinfection technology on Friday across various hospitals in Canada.
Company announcements Announcements
-
Nasal photodisinfection US market potential
19 February 2025 07:00
Ondine Biomedical Inc. NPV (CDI)
-
Ondine President increases shareholding
6 February 2025 11:00
Ondine Biomedical Inc. NPV (CDI)
-
Ondine CEO increases shareholding
4 February 2025 08:30
Ondine Biomedical Inc. NPV (CDI)
-
Appointment of Nominated and Financial Adviser
3 February 2025 07:00
Ondine Biomedical Inc. NPV (CDI)
-
CEO Increases Stake in Ondine
31 January 2025 10:03
Ondine Biomedical Inc. NPV (CDI)
-
Replacement: Director Increases Stake in Ondine
31 January 2025 09:52
Ondine Biomedical Inc. NPV (CDI)
-
Director Increases Stake in Ondine
31 January 2025 07:00
Ondine Biomedical Inc. NPV (CDI)
-
Notification of Major Holdings
30 January 2025 17:49
Ondine Biomedical Inc. NPV (CDI)
-
Notification of Major Holdings
29 January 2025 17:00
M&G
-
Grant of Options and Warrants
29 January 2025 07:15
Ondine Biomedical Inc. NPV (CDI)
-
HCA to invest US$4 million in Ondine
27 January 2025 07:00
Ondine Biomedical Inc. NPV (CDI)
-
Ondine recruits first patient for US Phase 3 trial
30 December 2024 07:00
Ondine Biomedical Inc. NPV (CDI)
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.